Core Viewpoint - Cullinan Therapeutics (CGEM) shows significant upside potential with a mean price target of $32.50, indicating a 292.5% increase from the current price of $8.28 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.74, where the lowest estimate is $29 (250.2% increase) and the highest is $36 (334.8% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can be a starting point for further research [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about CGEM's earnings prospects, with a positive trend in earnings estimate revisions indicating potential stock upside [11] - Over the last 30 days, one estimate has increased while there were no negative revisions, leading to a 3.6% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - CGEM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for near-term upside [13]
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know